Citadel Advisors’s Checkpoint Therapeutics CKPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-263
| Closed | -$877 | – | 14580 |
|
|
2024
Q4 | $842 | Sell |
263
-12,853
| -98% | -$43.6K | ﹤0.01% | 14262 |
|
|
2024
Q3 | $29.4K | Buy |
+13,116
| New | +$30.3K | ﹤0.01% | 12458 |
|
|
2024
Q2 | – | Sell |
-6,692
| Closed | -$11.9K | – | 14358 |
|
|
2024
Q1 | $13.7K | Buy |
+6,692
| New | +$13.3K | ﹤0.01% | 13283 |
|
|
2023
Q4 | – | Sell |
-1,898
| Closed | -$4.13K | – | 14343 |
|
|
2023
Q3 | $3.23K | Buy |
1,898
+1,138
| +150% | +$2.59K | ﹤0.01% | 13614 |
|
|
2023
Q2 | $1.88K | Buy |
+760
| New | +$2.08K | ﹤0.01% | 13860 |
|
|
2023
Q1 | – | Sell |
-64
| Closed | -$321 | – | 14795 |
|
|
2022
Q4 | $327 | Sell |
64
-1,598
| -96% | -$11.5K | ﹤0.01% | 14690 |
|
|
2022
Q3 | $17K | Sell |
1,662
-4,267
| -72% | -$50.8K | ﹤0.01% | 12127 |
|
|
2022
Q2 | $61K | Sell |
5,929
-12,053
| -67% | -$158K | ﹤0.01% | 11804 |
|
|
2022
Q1 | $318K | Buy |
17,982
+5,710
| +47% | +$123K | ﹤0.01% | 10465 |
|
|
2021
Q4 | $381K | Sell |
12,272
-8,161
| -40% | -$270K | ﹤0.01% | 10349 |
|
|
2021
Q3 | $674K | Buy |
20,433
+7,985
| +64% | +$236K | ﹤0.01% | 9162 |
|
|
2021
Q2 | $367K | Buy |
12,448
+6,154
| +98% | +$171K | ﹤0.01% | 10778 |
|
|
2021
Q1 | $198K | Buy |
+6,294
| New | +$211K | ﹤0.01% | 11714 |
|
|
2020
Q3 | – | Sell |
-2,221
| Closed | -$44K | – | 10125 |
|
|
2020
Q2 | $44K | Buy |
+2,221
| New | +$40.5K | ﹤0.01% | 9354 |
|
Citadel Advisors's CKPT Position: Q1 2025 in Review
Citadel Advisors sold out of Checkpoint Therapeutics (CKPT) in Q1 2025, closing a stake of 263 shares — an estimated $877 sold.
Citadel Advisors first reported a position in CKPT in Q2 2020 and held it in 14 quarters. The position peaked at $674K in Q3 2021. 84 funds tracked by Wall St. Rank hold CKPT as of Q1 2025.
- Citadel Advisors reported no remaining Checkpoint Therapeutics position as of Q1 2025 after selling out during the quarter.
- Citadel Advisors sold 263 Checkpoint Therapeutics shares in Q1 2025, an estimated $877.
- Citadel Advisors first reported a position in Checkpoint Therapeutics in Q2 2020 and held it in 14 quarters.
- Citadel Advisors's Checkpoint Therapeutics position peaked at $674K in Q3 2021.
- 84 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q1 2025.
Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.